Sunday 18 October 2026
Export ARTV’s income statement to Excel — free account
Artiva Biotherapeutics, Inc.
ARTV Healthcare Biotechnology
Artiva Biotherapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $251,000.00, down 99.3% from fiscal 2023. In the quarter to June 2026, EPS grew 27.6% and free cash flow grew 13.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
5.85
0.21
−3.47%
Follow ARTV
| Dec '25 | Dec '24 | Dec '23 | |
|---|---|---|---|
P/E ratio |
— | 0.00 | 0.00 |
Altman Z-Score |
— | 1.27 | — |
P/S ratio |
— | 0.00 | 0.00 |
P/FCF ratio |
— | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
— | 8.07 | (4.00) |
P/Operating CF |
— | (7.75) | (0.71) |
Beneish M-Score |
— | (22.63) | — |
P/B ratio |
— | 0.61 | 0.00 |
Price to Tangible BV |
— | 0.61 | 0.00 |
EV/Sales |
— | 0.00 | 0.00 |
EV/EBITDA |
— | 1.11 | 1.23 |
EV/Operating CF |
— | 1.31 | 0.73 |
EV/FCF |
— | 1.29 | 0.71 |
Quick Ratio |
8.26 | 15.15 | 6.44 |
Current Ratio |
8.61 | 15.39 | 6.53 |
Net Debt/EBITDA |
1.24 | 2.86 | 2.71 |
Debt/Assets |
0.00% | 0.02% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.92 | 0.84 | 1.65 |
Capex/Depreciation |
(1.00) | (0.26) | (1.44) |
| (56.55%) | (530.93%) | 0.00% | |
| (49.26%) | (41.55%) | 0.00% | |
ROIC |
(2,860.92%) | (3,345.37%) | 0.00% |
Return on Tangible Assets |
(78.97%) | (35.77%) | (37.94%) |
Average Days of Receivables |
0.00 | 212.31 | 19.16 |
Research and Development Expense of Revenue |
0.00% | 20,051.00% | 150.04% |
Selling, General and Administrative Expense of Revenue |
0.00% | 6,854.58% | 41.54% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 2,780.88% | 21.06% |
Graham Net Nets |
— | 1.46 | (22.32) |
Graham Number |
— | 0.00 | 0.00 |
Earnings Yield |
— | (57.60%) | (327.93%) |
Free Cash Flow Yield |
— | (49.06%) | (528.96%) |
Revenue per Share |
0.00 | 0.02 | 41.72 |
Operating CF per Share |
(3.14) | (4.89) | (59.09) |
Capex per Share |
(0.11) | (0.06) | (4.06) |
Free Cash Flow per Share |
(3.25) | (4.94) | (63.15) |
Cash per Share |
4.42 | 16.47 | 95.89 |
Shareholders Equity per Share |
4.50 | 16.58 | (201.84) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 |
Book value per Share |
4.50 | 16.58 | (201.84) |
Free Cash Flow |
(79.34) | (55.67) | (50.69) |
Working Capital |
99.58 | 176.38 | 67.59 |
Capital Expenditures |
(2.59) | (0.64) | (3.26) |
Net Current Asset Value |
91.70 | 165.69 | (187.31) |
EV/EBIT |
— | 1.07 | 1.16 |
Capex to Sales |
0.00 | 2.56 | 0.10 |
Price to Operating Income |
— | 0.00 | 0.00 |
| Other line items | |||
Depreciation/Fixed assets |
0.39 | 0.38 | 0.28 |
Cash ROIC |
(36.40%) | (14.96%) | 59.60% |
Accounts Receivable Turnover |
0.00 | 0.26 | 0.00 |
Accounts Payable Turnover |
0.00 | 0.00 | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 |
Average Receivables |
0.11 | 0.95 | — |
Average Payables |
0.74 | 0.87 | — |
Average Assets |
170.26 | 157.35 | — |
Average Common Equity |
148.31 | 12.31 | — |
Columns are period end dates